Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Onxeo. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Onxeo's earnings available for a low price, and how does
this compare to other companies in the same industry?
Onxeo is not considered high growth as it is expected to be loss making for the next 1-3 years.
Onxeo's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Onxeo's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operations and R&D at Onxeo SA since March 1, 2011. Ms. Greciet served as Deputy Chief Operating Officer of BioAlliance Pharma since March 2011. Ms. Greciet has an exemplary career in the pharmaceutical industry and international groups. Ms. Greciet joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (Laboratoire Francais du fractionnement et des Biotechnologies, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she held increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities.). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects. She has been a Director of Onxeo SA since June 29, 2011. She holds a Doctorate of Pharmacy in addition to being a graduate of 3(rd) cycle management and pharmaceutical marketing.
Judith's compensation has increased whilst company is loss making.
Judith's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Onxeo management team is about average.
CEO & Director
Chief Financial Officer
Chief Scientific Officer
Director of Human Resources
Chief Pharmacist & Quality Assurance Director
Chief of US Operations and Executive Vice President
Olivier de Beaumont
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Onxeo board of directors is less than 3 years, this suggests a new board.
Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops Beleodaq for the treatment of others liquid or solid tumors; AsiDNA, which is in Phase I clinical trial for the treatment of metastatic melanoma; Livatag that is in Phase III clinical trial to treat advanced primary liver cancer; and Validive, which is in Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; and a license agreement with Monopar Therapeutics Inc. to develop Validive. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.